Here's what happened in life sciences this past week đź’Šđź“°

General

Why Apple, Amazon, and Google are making big health care moves. Link

Why potentially dodgy diabetes drugs dominate in India. Link

The rising power of oncology clinical data companies. Link

In two months, biotech startups raised more money than in all of 2013. Link

How medicine's long, thin supply chain threatens Americans. Link 

Probe into generic drug price fixing set to widen. Link

Merck shells out $300 million to partner Eisai in cancer drug deal. Link

Digital Health

Xbox for Docs: Pharma backs AR games for use in physician learning. Link

How a remote-controlled robotic pill could be the next breakthrough in digital health. Link

Mayo Clinic finds IBM Watson boost in clinical trial enrollment. Link

Research

Immunotherapy: beyond melanoma and lung cancer treatment. Link

Could our blood reveal our future dementia risk? Link

Four stories of antibacterial breakthroughs. Link

Perspective and Opinions

Bringing down the cost of cancer treatment. Link

What will healthcare look like once smart speakers are everywhere? Link

Interesting

An exercise pill may be in the future for those incapable of working out. Link

How rats could help reduce the global TB burden. Link

Startups of the Week / Notable Deals

Cyteir Therapeutics is targeting diseases with a gain-of-function in AID (Autoimmune disease). The advantages of this gain-of-function approach include potentially broader applicability, reduced side effects, and simpler, sensitive companion diagnostics for patient selection. Closed a $29m Series B financing.

Micropep focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact. Raised €4M in Series A funding.

Medial EarlySign provides an advanced AI-based algorithm platform for healthcare organizations to stratify populations to optimize care for individuals and prevent or delay serious health conditions, by leveraging routine blood test results, and common labs and EHR data. Completed a $30m Series B financing

Owlstone Medical is advancing the Breath Biopsy platform for early detection and precision medicine, with applications in cancer and a wide range of other conditions. Raised $15m in funding.